Sialylated HMO has many benefits, including maintaining intestinal health, assisting brain development, and promoting the development of cognitive function, and has broad application prospects in the fields of biomedicine and functional food. In this regard, CD BioGlyco has accumulated many years of scientific research experience to provide you with a one-stop service for the production of sialylated HMO.
Human milk is rich in sialic acids, which are usually combined with oligosaccharides and glycoconjugates. Sialylated HMO is an essential functional sugar, which accounts for 12.6 – 21.9% of total free oligosaccharides in human milk. At present, the characterization of sialylated HMO compounds has become more and more comprehensive, and the corresponding biological functions have been continuously discovered. It has become the direction of scientists' efforts to imitate the proportion of formula in human milk and expect sialylated HMO to be used as an ingredient of infant formula milk powder to help the healthy growth of infants.
Fig.1 The sialylated structures in breast milk. (Wang, et al., 2021)
Sialylated HMOs include 3'-sialyllactose, disialyllacto-N-tetraose, α2,3-Sialyllacto-N-biose, and other oligosaccharides. It exhibits multiple health effects, some of which are listed as follows:
Generally, Sialylated HMOs are not easy to digest. When they are absorbed into the intestinal circulatory system, they shape intestinal microbiota and promote the proliferation of bifidobacteria and other beneficial bacteria.
Some Sialylated HMOs can block the NF-κB signal pathway, inhibit the expression of catabolic factors, and the proliferation of inflammatory immune cells, thereby regulating the inflammatory response.
Some sialylated HMOs show a variety of positive physiological functions, such as anti-adhesive antimicrobial ability, antiviral activity, regulation of intestinal epithelial cell responses, immunomodulatory activity, regulation of endothelial cell permeability, promotion of brain development, and cognitive improvement.
CD BioGlyco has accumulated many advanced and mature production methods, including biotransformation, chemical synthesis, separation, and purification. Sialylated HMOs we have produced include but are not limited to the varieties listed in the following table. On the other hand, we are also expanding the production scope of this type of HMO.
CD BioGlyco has a variety of synthesis routes for Sialylated HMO to meet client needs. If you have any questions, please contact us directly for more detail.
Reference
